HOUSTON, April 8, 2025 /PRNewswire/ — SPL Environmental, a leader in analytical laboratory testing, is proud to announce the addition of targeted dioxin testing for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) to its suite of advanced, specialty laboratory services.
2,3,7,8-TCDD is the most toxic and well-studied of the dioxin compounds and is commonly monitored in regulatory and environmental compliance programs. By offering testing for this compound, SPL supports public water suppliers, wastewater treatment plants, industries, and environmental consultants in meeting stringent safety and environmental standards.
“Adding dioxin testing enhances our ability to provide high-quality data for clients managing contamination concerns and regulatory compliance,” said Andrew Parker, President, Environmental at SPL. “It’s another way we’re partnering with our customers, helping them navigate complex environmental requirements with confidence.”
While SPL is accredited to test 2,3,7,8-TCDD in drinking water, this service is also applicable to:
With a legacy of scientific excellence and a dedicated team of experts, SPL continues to expand its specialized testing capabilities to support public health, environmental protection, and regulatory compliance.
For more information about Dioxin testing, or to request a quote, please visit www.spllabs.com.
About SPL
SPL is a leading provider of compliance and testing services for Environmental, Energy, and other end markets. Through our ISO and NELAP certified labs, verifiable test methods, and nationally recognized scientists SPL is dedicated to ensuring accurate and defensible data to our clients and communities. We provide best-in-class laboratory, metrology, and data management services, as well as access to data in real-time, to enable our customers to efficiently track and optimize their operations.
SOURCE SPL, Inc.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE…
VANCOUVER, BC / ACCESS Newswire / December 18, 2025 / 1933 Industries Inc. (the "Company"…
Strategic collaboration aims to enhance operational efficiency and mitigate risks by transitioning to a business…
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…
BOSTON, Dec. 17, 2025 /PRNewswire/ -- CranioSense, Inc., a neurotechnology company developing the world's first noninvasive…
TORRINGTON, Conn., Dec. 17, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…